GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » GF Score
中文

Guardant Health (Guardant Health) GF Score : 66/100 (As of Apr. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Guardant Health GF Score?

Guardant Health has the GF Score of 66, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 3/10
2. Profitability Rank : 3/10
3. Growth Rank : 9/10
4. GF Value Rank : 2/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Guardant Health might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Guardant Health's GF Score

For the Diagnostics & Research subindustry, Guardant Health's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health's GF Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's GF Score distribution charts can be found below:

* The bar in red indicates where Guardant Health's GF Score falls into.



Guardant Health  (NAS:GH) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


Guardant Health GF Score Related Terms

Thank you for viewing the detailed overview of Guardant Health's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health (Guardant Health) Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Executives
Meghan V. Joyce director THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Kumud Kalia officer: Chief Information Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Ines Dahne-steuber officer: Chief Operating Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova officer: Chief Technology Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy director, officer: Chief Executive Officer 2 BARRY LANE, ATHERTON CA 94027
Amirali Talasaz director, officer: Chairman, President and COO 18 ISABELLA AVENUE, ATHERTON CA 94027
Musa Tariq director 3100 HANOVER STREET, PALO ALTO CA 94304
Amelia Merrill officer: SVP, People 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman director 2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Chris Freeman officer: Chief Commercial Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Bahija Jallal director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Vijaya Gadde director C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103